Orchard Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2022	2021	2020	2019	2018	2017	2016
Revenue	22.66	1.68	2.6	2.51	2.08	0	0
Revenue Growth (YoY)	1252.54%	-35.45%	3.26%	21.05%	-	-	-
Cost of Revenue	6.77	0.23	0.86	0.81	0.42	0	0
Gross Profit	15.88	1.45	1.74	1.71	1.65	0	0
Selling, General & Admin	49.13	54.91	64.99	57.22	31.37	5.99	3
Research & Development	93.85	86.98	93.73	117.36	205.32	32.53	16.21
Operating Expenses	142.97	141.88	158.72	174.58	236.69	38.51	19.2
Operating Income	-127.09	-140.43	-156.98	-172.87	-235.03	-38.51	-19.2
Interest Expense / Income	3.08	2.5	2.33	1.54	0	0	0
Other Expense / Income	22.87	0.83	-6.6	-8.75	-5.51	1.18	-0.14
Pretax Income	-153.03	-143.76	-152.71	-165.66	-229.53	-39.69	-19.07
Income Tax	-2.37	0.83	-0.73	-2.24	0.97	0.05	0.02
Net Income	-150.66	-144.58	-151.98	-163.42	-230.5	-39.74	-19.09
Shares Outstanding (Basic)	128	124	99	93	23	9	7
Shares Outstanding (Diluted)	128	124	99	93	23	9	7
Shares Change	3.24%	24.65%	6.66%	313.31%	154.25%	24.96%	-
EPS (Basic)	-11.80	-11.70	-15.30	-17.50	-102.20	-44.80	-26.90
EPS (Diluted)	-11.80	-11.70	-15.30	-17.50	-102.20	-44.80	-26.90
Free Cash Flow	-74.54	-127.23	-137.07	-170.5	-101.57	-34.05	-14.76
Free Cash Flow Per Share	-5.82	-10.26	-13.78	-18.29	-45.02	-38.37	-20.78
Gross Margin	70.11%	86.51%	66.97%	67.97%	79.67%	-	-
Operating Margin	-560.97%	-8384.06%	-6049.25%	-6879.15%	-11321.34%	-	-
Profit Margin	-665.02%	-8631.88%	-5856.61%	-6503.06%	-11102.84%	-	-
Free Cash Flow Margin	-329.00%	-7595.76%	-5281.93%	-6784.64%	-4892.49%	-	-
EBITDA	-147.21	-138.93	-148.38	-162.45	-228.33	-39.39	-19.06
EBITDA Margin	-649.81%	-8294.45%	-5717.84%	-6464.35%	-10998.36%	-	-
Depreciation & Amortization	2.74	2.33	2	1.68	1.2	0.3	0.01
EBIT	-149.96	-141.26	-150.38	-164.12	-229.53	-39.69	-19.07
EBIT Margin	-661.91%	-8433.37%	-5795.07%	-6531.00%	-11056.12%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).